Kaida BioPharma to Present at the Virtual Investor Pitch Conference
17 Junio 2024 - 6:30AM
Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma
company dedicated to advancing ovarian cancer treatment through
innovative drug development, today announced that it will present
at the Virtual Investor Pitch Conference today, June 17, 2024 at
9:00 AM ET.
As part of the event, Craig Pierson, Founder and
Chairman of Kaida BioPharma, will provide an “elevator pitch” and
outline the Company’s upcoming milestones. Additionally, investors
and interested parties will have the opportunity to submit
questions live during the event. Participating companies will
answer as many questions as possible in the time allowed.
A live video webcast will be accessible on the
event website, virtualinvestorco.com. A webcast replay will be
available two hours following the live event and will be accessible
for 90 days.
About Kaida BioPharma
Kaida BioPharma was founded on the research
principles and clinical evidence of G129R, a growth hormone
antagonist that has shown to induce programmed cell death
(autophagy) in gynecologic tumors. Our collaboration with Dr. John
Langenheim, professor at Thomas Jefferson University and Dr. Anil
Sood at MD Anderson, who have published extensive research on
G129R, has provided solutions we intend to bring to the clinic. At
Kaida, we are dedicated to providing a new hope for patients with
treatment-resistant gynecological cancers. Our mission is to
develop innovative therapies that target the specific needs of
those patients, offering a medical treatment that can make a
significant difference. For more information, please visit
kaida-biopharma.com.
Investor ContactJenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247E: kaida@jtcir.com